Market Overview

UPDATE: Dawson James Initiates Celsion at Market Outperform on Phase III Catalyst

Related CLSN
15 Biggest Mid-Day Losers For Thursday
Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet

Dawson James initiated coverage on Celsion (NASDAQ: CLSN) with a Market Outperform rating and a $9 price target.

Dawson James said, "In our opinion, should the HEAT trial read out positively as we expect, it will not only be viewed by investors as a validation of the market opportunity for ThermoDox, but for the entire clinical development strategy across multiple tumor types with significant commercial potential. It is worth noting that CLSN owns all the worldwide rights to ThermoDox with the exception of Japan. A future corporate collaboration could be yet another material value-driver in a reasonable (12-18 month) investment time horizon."

Celsion closed at $6.66 on Monday.

Latest Ratings for CLSN

Jul 2015Maxim GroupInitiates Coverage onBuy
Jul 2015BTIG ResearchInitiates Coverage onBuy
Oct 2014Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for CLSN
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (CLSN)

View Comments and Join the Discussion!